Non-Compliance with Anti-Corruption Provision Sample Clauses

Non-Compliance with Anti-Corruption Provision. If CRO or Pfizer terminates the Study because of Principal Investigator’s or Institution’s non-compliance with the terms of Section 20, Anti-Corruption, CRO and Pfizer will not provide any further payment under this Agreement, regardless of any activities that Principal Investigator or Institution has undertaken or third-party agreements that Principal Investigator or Institution has entered into before termination.
Sample 1Sample 2Sample 3See All (10)
AutoNDA by SimpleDocs
Non-Compliance with Anti-Corruption Provision. If CRO or Pfizer terminates the Study because of Principal Investigator’s or Institution’s non-compliance with the terms of Section 20, Anti-Corruption, CRO and Pfizer will not provide any further payment under this Agreement, regardless of any activities that Principal Investigator or Institution has undertaken or third-party agreements that Principal Investigator or Institution has entered into before termination. a. Nedodržení protikorupčních opatření. Pokud CRO nebo společnost Pfizer Smlouvu předčasně ukončí z důvodu nedodržení podmínek článku 20 (Protikorupční opatření) této Smlouvy Hlavním zkoušejícím nebo Institucí, CRO a společnost Pfizer neuhradí žádné další platby podle této Smlouvy bez ohledu na to, zda Hlavní zkoušející nebo Instituce vykonali před ukončením Smlouvy jakékoli činnosti nebo uzavřeli jakékoli dohody se třetími stranami.
Sample 1
Non-Compliance with Anti-Corruption Provision. If CRO or Pfizer terminates the Study because of Institution’s and Principal Investigator’s non-compliance with the terms of Section 20, Anti-Corruption, CRO and Pfizer will not provide any further payment under this Agreement, regardless of any activities that Institution and Principal a. Nedodržování protikorupčních ustanovení. Pokud CRO nebo společnost Pfizer ukončí studii z důvodu nedodržení podmínek odstavce 20, Protikorupční zásady, ze strany zdravotnického zařízení a hlavního zkoušejícího, CRO a společnost Pfizer neuhradí žádné další platby podle této smlouvy, a to bez ohledu na jakékoli činnosti, které zdravotnické zařízení a hlavní zkoušející provedli, Investigator have undertaken or third-party agreements that Institution and Principal Investigator have entered into before termination. nebo smlouvy se třetími stranami, které zdravotnické zařízení a hlavní zkoušející uzavřeli před ukončením studie.
Sample 1
Non-Compliance with Anti-Corruption Provision. If CRO or Pfizer terminates the Study because of Institution’s a. Nedodržování protikorupčních ustanovení. Pokud CRO nebo společnost Pfizer ukončí studii z důvodu and Principal Investigator’s non- compliance with the terms of Section 20, Anti- Corruption, CRO and Pfizer will not provide any further payment under this Agreement, regardless of any activities that Institution and Principal Investigator have undertaken or third-party agreements that Institution and Principal Investigator have entered into before termination. nedodržení podmínek odstavce 20, Protikorupční zásady, ze strany zdravotnického zařízení a hlavního zkoušejícího, CRO a společnost Pfizer neuhradí žádné další platby podle této smlouvy, a to bez ohledu na jakékoli činnosti, které zdravotnické zařízení a hlavní zkoušející provedli, nebo smlouvy se třetími stranami, které zdravotnické zařízení a hlavní zkoušející uzavřeli před ukončením studie.
Sample 1
Non-Compliance with Anti-Corruption Provision. If CRO or Pfizer terminates the Study because of Institution’s or Principal Investigator’s non-compliance with the terms of Section 20, Anti-Corruption, CRO and Pfizer will not provide any further payment under this Agreement, regardless of any activities that Institution has undertaken or third-party agreements that Institution has entered into before termination. a. Nedodržanie protikorupčného ustanovenia. Ak CRO alebo spoločnosť Pfizer ukončí klinické skúšanie, pretože inštitúcia alebo hlavný skúšajúci nedodržali podmienky časti 20, Protikorupčné opatrenia, CRO a spoločnosť Pfizer neposkytnú žiadne ďalšie platby v rámci tejto zmluvy, nezávisle od akýchkoľvek aktivít, ktoré inštitúcia vykonáva, či zmlúv s tretími stranami, ktoré inštitúcia uzavrela pred ukončením zmluvy.
Sample 1
Non-Compliance with Anti-Corruption Provision. If CRO or Pfizer terminates the Study because of the Health Services Provider’s or Principal Investigator’s non- compliance with the terms of Section 20, Anti-Corruption, CRO and Pfizer will not provide any further payment under this Agreement. a. N edodržení protikorupčních opatření. Pokud CRO nebo společnost Pfizer Smlouvu předčasně ukončí kvůli nedodržení podmínek článku 20 (Protikorupční opatření) této Smlouvy Poskytovatelem zdravotních služeb nebo Hlavním zkoušejícím, CRO a společnost Pfizer neuhradí žádné další platby podle této Smlouvy.
Sample 1
Non-Compliance with Anti-Corruption Provision. If CRO or XXX terminates the Study because of Institution’s or Principal Investigator´s non- compliance with the terms of Section 20, Anti-Corruption, CRO and XXX will not provide any further payment under this Agreement, regardless of any activities that Institution has undertaken or third-party agreements that Institution has entered into before termination. zkoušející mohou Studii ukončit okamžikem oznámení CRO, pokud je o to požádá odpovědná komise IRB/IEC.
Sample 1
AutoNDA by SimpleDocs

Related to Non-Compliance with Anti-Corruption Provision

  • Compliance with Anti-Corruption Laws Neither the Company nor any of its Controlled Entities or their respective affiliates, nor any director, officer or employee thereof nor, to the Company’s knowledge, any agent or representative of the Company or of any of its Controlled Entities or their respective affiliates, has (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (ii) taken or will take any action in furtherance of an offer, payment, promise to pay, or authorization or approval of the payment, giving or receipt of money, property, gifts or anything else of value, directly or indirectly, to any “government official” (including any officer, director or employee of a government or government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office) to induce such government official to do or omit to do any act in violation of his lawful duties, influence official action or secure, obtain or retain business or any other improper advantage; (iii) made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or improper payment or benefit; or (iv) will use, directly or indirectly, the proceeds of the offering in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to any person in violation of any applicable anti-bribery or anti-corruption laws, in each case as amended from time to time, (collectively, the “Anti-Corruption Laws”); and the Company and its Controlled Entities and affiliates have conducted their businesses in compliance with Anti-Corruption Laws and have instituted, maintained and enforced, and will continue to maintain and enforce, policies and procedures reasonably designed to promote and achieve compliance with such laws and with the representations and warranties contained herein; no investigation, action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its Controlled Entities with respect to the Anti-Corruption Laws is pending or, to the best knowledge of the Company after due and careful inquiry, threatened.

  • Compliance with Anti-Terrorism Laws Collateral Agent hereby notifies Borrower and each of its Subsidiaries that pursuant to the requirements of Anti-Terrorism Laws, and Collateral Agent’s policies and practices, Collateral Agent is required to obtain, verify and record certain information and documentation that identifies Borrower and each of its Subsidiaries and their principals, which information includes the name and address of Borrower and each of its Subsidiaries and their principals and such other information that will allow Collateral Agent to identify such party in accordance with Anti-Terrorism Laws. Neither Borrower nor any of its Subsidiaries shall, nor shall Borrower or any of its Subsidiaries permit any Affiliate to, directly or indirectly, knowingly enter into any documents, instruments, agreements or contracts with any Person listed on the OFAC Lists. Borrower and each of its Subsidiaries shall immediately notify Collateral Agent if Borrower or such Subsidiary has knowledge that Borrower, or any Subsidiary or Affiliate of Borrower, is listed on the OFAC Lists or (a) is convicted on, (b) pleads nolo contendere to, (c) is indicted on, or (d) is arraigned and held over on charges involving money laundering or predicate crimes to money laundering. Neither Borrower nor any of its Subsidiaries shall, nor shall Borrower or any of its Subsidiaries, permit any Affiliate to, directly or indirectly, (i) conduct any business or engage in any transaction or dealing with any Blocked Person, including, without limitation, the making or receiving of any contribution of funds, goods or services to or for the benefit of any Blocked Person, (ii) deal in, or otherwise engage in any transaction relating to, any property or interests in property blocked pursuant to Executive Order No. 13224 or any similar executive order or other Anti-Terrorism Law, or (iii) engage in or conspire to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the prohibitions set forth in Executive Order No. 13224 or other Anti-Terrorism Law.

  • Compliance with FCPA Each of the Credit Parties and their Subsidiaries is in compliance with the Foreign Corrupt Practices Act, 15 U.S.C. §§ 78dd-1, et seq., and any foreign counterpart thereto. None of the Credit Parties or their Subsidiaries has made a payment, offering, or promise to pay, or authorized the payment of, money or anything of value (a) in order to assist in obtaining or retaining business for or with, or directing business to, any foreign official, foreign political party, party official or candidate for foreign political office, (b) to a foreign official, foreign political party or party official or any candidate for foreign political office, and (c) with the intent to induce the recipient to misuse his or her official position to direct business wrongfully to such Credit Party or its Subsidiary or to any other Person, in violation of the Foreign Corrupt Practices Act, 15 U.S.C. §§ 78dd-1, et seq.

  • Compliance with Anti-Corruption Laws and Sanctions Maintain in effect and enforce policies and procedures designed to ensure compliance by the Borrower, its Subsidiaries and their respective directors, officers, employees and agents with Anti-Corruption Laws and applicable Sanctions.

  • Compliance with Agreement Buyer shall have performed and complied in all material respects with all of its obligations under this Agreement which are to be performed or complied with by it prior to or on the Closing Date.

  • Compliance with Agreements and Law Each Restricted Person will perform all material obligations it is required to perform under the terms of each indenture, mortgage, deed of trust, security agreement, lease, franchise, agreement, contract or other instrument or obligation to which it is a party or by which it or any of its properties is bound. Each Restricted Person will conduct its business and affairs in compliance with all Laws applicable thereto.

  • Compliance with Act The holder of this Warrant, by acceptance hereof, agrees that this Warrant, and the Shares to be issued upon exercise hereof and any Common Stock issued upon conversion thereof are being acquired for investment and that such holder will not offer, sell or otherwise dispose of this Warrant, or any Shares to be issued upon exercise hereof or any Common Stock issued upon conversion thereof except under circumstances which will not result in a violation of the Securities Act of 1933, as amended (the “Act”) or any applicable state securities laws. Upon exercise of this Warrant, unless the Shares being acquired are registered under the Act and any applicable state securities laws or an exemption from such registration is available, the holder hereof shall confirm in writing that the Shares so purchased (and any shares of Common Stock issued upon conversion thereof) are being acquired for investment and not with a view toward distribution or resale in violation of the Act and shall confirm such other matters related thereto as may be reasonably requested by the Company. This Warrant and all Shares issued upon exercise of this Warrant and all shares of Common Stock issued upon conversion thereof (unless registered under the Act and any applicable state securities laws) shall be stamped or imprinted with a legend in substantially the following form: “THE SECURITIES EVIDENCED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM THE APPROPRIATE GOVERNMENTAL AUTHORITIES, OR (iv) OTHERWISE COMPLYING WITH THE PROVISIONS OF SECTION 7 OF THE WARRANT UNDER WHICH THESE SECURITIES WERE ISSUED, DIRECTLY OR INDIRECTLY. THE SHARES ISSUABLE HEREUNDER ARE SUBJECT TO (1) RESTRICTIONS ON TRANSFERABILITY AND RESALE, INCLUDING A LOCK-UP PERIOD OF UP TO 180 DAYS (SUBJECT TO CERTAIN EXTENSIONS) IN THE EVENT OF AN INITIAL PUBLIC OFFERING, AS SET FORTH IN AN INVESTORS’ RIGHTS AGREEMENT, AND (2) VOTING RESTRICTIONS AS SET FORTH IN A VOTING AGREEMENT, COPIES OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE COMPANY.” Said legend shall be removed by the Company, upon the request of a holder, at such time as the restrictions on the transfer of the applicable security shall have terminated. In addition, in connection with the issuance of this Warrant, the holder specifically represents to the Company by acceptance of this Warrant as follows: (1) The holder is aware of the Company’s business affairs and financial condition, and has acquired information about the Company sufficient to reach an informed and knowledgeable decision to acquire this Warrant. The holder is acquiring this Warrant for its own account for investment purposes only and not with a view to, or for the resale in connection with, any “distribution” thereof in violation of the Act. (2) The holder understands that this Warrant has not been registered under the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the holder’s investment intent as expressed herein. (3) The holder further understands that this Warrant must be held indefinitely unless subsequently registered under the Act and qualified under any applicable state securities laws, or unless exemptions from registration and qualification are otherwise available. The holder is aware of the provisions of Rule 144, promulgated under the Act. (4) The holder is an “accredited investor” as such term is defined in Rule 501 of Regulation D promulgated under the Act.

  • Compliance with Agreements Promptly and fully comply with all Contractual Obligations to which any one or more of them is a party, except for any such Contractual Obligations (a) the nonperformance of which would not cause a Default or Event of Default, (b) then being contested by any of them in good faith by appropriate proceedings, or (c) if the failure to comply therewith could not reasonably be expected to have a Material Adverse Effect.

  • Provide Data in Compliance with Applicable Laws LEA shall provide Student Data for the purposes of obtaining the Services in compliance with all applicable federal, state, and local privacy laws, rules, and regulations, all as may be amended from time to time.

  • Compliance with Agreements, Laws, Etc It shall (i) duly observe and comply in all material respects with all Applicable Laws relative to the conduct of its business or to its assets, (ii) preserve and keep in full force and effect its legal existence, (iii) preserve and keep in full force and effect its rights, privileges, qualifications and franchises, except where the failure to do so could not reasonably be expected to result in a Material Adverse Effect, (iv) comply with the terms and conditions of each Facility Document to which it is a party and its Constituent Documents and (v) obtain, maintain and keep in full force and effect all Governmental Authorizations, Private Authorizations and Governmental Filings which are necessary to properly carry out its business and the transactions contemplated to be performed by it under the Facility Documents to which it is a party and its Constituent Documents, except, in the case of this clause (v), where the failure to do so would not reasonably be expected to have a Material Adverse Effect.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!